Isto gains cash boost for neocartilage allograft:
This article was originally published in Clinica
Executive Summary
Isto Technologies has gained a $750,000 US grant to fund the continued development of a tissue-engineered neocartilage allograft for the surgical repair of focal articular cartilage defects in the knee and other joints. The award from the National Institute of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, will fund research to assess the allograft in sheep. The St Louis, Missouri firm estimates that the market potential for a "superior" cartilage repair technology exceeds $1bn in the US alone. Isto is also developing an osteochondral allograft that may be more suitable for osteoarthritic lesions.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.